• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

《灯盏生脉活性成分通过NMDA受体介导的Ca/CaMKII途径促进海马长时程增强改善认知障碍》的勘误 [《药物分析杂志》14 (2024) 435 - 438]

Corrigendum to "Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca/CaMKII pathway" [J. Pharm. Anal. 14 (2024) 435-438].

作者信息

Ma Congyu, Sheng Ning, Wu Jun, Wang Lulu, Jiang Jiandong, Yu Haibo, Zhang Jinlan

机构信息

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.

出版信息

J Pharm Anal. 2024 Jun;14(6):101025. doi: 10.1016/j.jpha.2024.101025. Epub 2024 Jul 9.

DOI:10.1016/j.jpha.2024.101025
PMID:39077507
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11284492/
Abstract

[This corrects the article DOI: 10.1016/j.jpha.2023.09.016.].

摘要

[本文更正了文章的数字对象标识符：10.1016/j.jpha.2023.09.016。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/473c/11284492/4052e6fab492/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/473c/11284492/4052e6fab492/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/473c/11284492/4052e6fab492/fx1.jpg

相似文献

1
Corrigendum to "Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca/CaMKII pathway" [J. Pharm. Anal. 14 (2024) 435-438].《灯盏生脉活性成分通过NMDA受体介导的Ca/CaMKII途径促进海马长时程增强改善认知障碍》的勘误 [《药物分析杂志》14 (2024) 435 - 438]
J Pharm Anal. 2024 Jun;14(6):101025. doi: 10.1016/j.jpha.2024.101025. Epub 2024 Jul 9.
2
Active components of Dengzhan Shengmai ameliorate cognitive impairment by facilitating hippocampal long-term potentiation via the NMDA receptor-mediated Ca/CaMKII pathway.灯盏生脉的活性成分通过NMDA受体介导的Ca/CaMKII途径促进海马长时程增强，从而改善认知障碍。
J Pharm Anal. 2024 Mar;14(3):435-438. doi: 10.1016/j.jpha.2023.09.016. Epub 2023 Sep 27.
3
Multi-omics reveals Dengzhan Shengmai formulation ameliorates cognitive impairments in D-galactose-induced aging mouse model by regulating CXCL12/CXCR4 and gut microbiota.多组学揭示灯盏生脉方通过调节CXCL12/CXCR4和肠道微生物群改善D-半乳糖诱导的衰老小鼠模型中的认知障碍。
Front Pharmacol. 2023 Apr 10;14:1175970. doi: 10.3389/fphar.2023.1175970. eCollection 2023.
4
Corrigendum to "Nitrosamines crisis in pharmaceuticals - Insights on toxicological implications, root causes and risk assessment: A systematic review" [J. Pharm. Anal. 14 (2024) 100919].《药品中的亚硝胺危机——关于毒理学影响、根本原因和风险评估的见解：一项系统综述》的勘误 [《药物分析杂志》14 (2024) 100919]
J Pharm Anal. 2024 Jun;14(6):101033. doi: 10.1016/j.jpha.2024.101033. Epub 2024 Jul 9.
5
Corrigendum to "GB7 acetate, a alkaloid from , possesses anticancer effects in colorectal cancer cells" [J. Pharm. Anal. 12 (2022) 339-349].《GB7 乙酸盐，一种来自[具体来源]的生物碱，对结肠癌细胞具有抗癌作用》的勘误[《药物分析杂志》12 (2022) 339 - 349]
J Pharm Anal. 2023 Dec;13(12):1580-1582. doi: 10.1016/j.jpha.2023.12.014. Epub 2023 Dec 27.
6
Corrigendum to "Targeted metabolomics reveals the aberrant energy status in diabetic peripheral neuropathy and the neuroprotective mechanism of traditional Chinese medicine JinMaiTong" [J. Pharm. Anal. 14 (2024) 225-243].《靶向代谢组学揭示糖尿病周围神经病变中的能量代谢异常及中药金脉通的神经保护机制》的勘误 [《药物分析杂志》14 (2024) 225 - 243]
J Pharm Anal. 2024 Apr;14(4):100980. doi: 10.1016/j.jpha.2024.100980. Epub 2024 May 10.
7
Corrigendum to "The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review" [J. Pharma. Anal. 11 (2021) 265-271].《基于微小RNA的疗法在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染中的潜力：综述》[《药物分析杂志》11（2021）265 - 271]的勘误
J Pharm Anal. 2022 Dec;12(6):937. doi: 10.1016/j.jpha.2022.11.001. Epub 2022 Dec 21.
8
Retraction notice to "A DNA-based nanocarrier for efficient cancer therapy" [J. Pharm. Anal. 11 (2021) 330-339].对《一种用于高效癌症治疗的基于DNA的纳米载体》[《药物分析杂志》11 (2021) 330 - 339]的撤稿通知。
J Pharm Anal. 2021 Jun;11(3):R1. doi: 10.1016/j.jpha.2024.100963. Epub 2024 Mar 19.
9
4,5 caffeoylquinic acid and scutellarin, identified by integrated metabolomics and proteomics approach as the active ingredients of Dengzhan Shengmai, act against chronic cerebral hypoperfusion by regulating glutamatergic and GABAergic synapses.通过整合代谢组学和蛋白质组学方法鉴定出的 4,5-咖啡酰奎宁酸和野黄芩苷是灯盏生脉的活性成分，通过调节谷氨酸能和 GABA 能突触发挥对慢性脑低灌注的作用。
Pharmacol Res. 2020 Feb;152:104636. doi: 10.1016/j.phrs.2020.104636. Epub 2020 Jan 8.
10
Active calcium/calmodulin-dependent protein kinase II (CaMKII) regulates NMDA receptor mediated postischemic long-term potentiation (i-LTP) by promoting the interaction between CaMKII and NMDA receptors in ischemia.活性钙/钙调蛋白依赖性蛋白激酶 II（CaMKII）通过促进缺血时 CaMKII 与 NMDA 受体之间的相互作用来调节 NMDA 受体介导的缺血后长期增强（i-LTP）。
Neural Plast. 2014;2014:827161. doi: 10.1155/2014/827161. Epub 2014 Mar 10.